Results for tag: "Betrixaban"

Betrixaban is a hematological drug used to reduce the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation. It is a Factor Xa inhibitor, a type of anticoagulant that works by blocking the action of Factor Xa, an enzyme involved in the clotting process. Betrixaban is administered orally and is available in tablet form. It is typically prescribed for patients who are unable to take other anticoagulants, such as warfarin, due to drug interactions or other medical conditions. Betrixaban is a relatively new drug, having been approved by the US Food and Drug Administration in 2018. It is currently marketed by Portola Pharmaceuticals, Inc. in the United States and by Bayer AG in Europe. Betrixaban is also being studied for its potential use in other medical conditions, such as deep vein thrombosis and pulmonary embolism. Companies in the Betrixaban market include Portola Pharmaceuticals, Inc., Bayer AG, and Daiichi Sankyo Company, Ltd. Show Less Read more